Effectiveness of biologics in Australian patients with rheumatoid arthritis: a large observational study: REAL
| dc.contributor.author | Nicholls, Dave | |
| dc.contributor.author | Barrett, Rina | |
| dc.contributor.author | Button, Peter | |
| dc.contributor.author | Truman, Matt | |
| dc.contributor.author | BIRD, Paul | |
| dc.contributor.author | Roberts, L | |
| dc.contributor.author | Tymms, Kathleen | |
| dc.contributor.author | Littlejohn, Geoffrey | |
| dc.contributor.author | Griffiths, Hedley | |
| dc.date.accessioned | 2021-02-01T05:08:51Z | |
| dc.date.issued | 2018 | |
| dc.date.updated | 2020-11-02T04:24:40Z | |
| dc.description.abstract | Background: The comparative effectiveness of biologic treatment regimens in a real world Australian population is unknown. Aim: To assess the effectiveness of biological disease-modifying anti-rheumatic drugs (bDMARD) as monotherapy or in combination with methotrexate and/or other conventional DMARD (cDMARD) for the treatment of rheumatoid arthritis (RA). Methods: A retrospective, non-interventional study was conducted that investigated the use of bDMARD in adult patients with RA in routine clinical practice. Data were extracted from the Optimising Patient Outcomes in Australian Rheumatology – Quality Use of Medicines Initiative database. Real-world effectiveness was measured using the 28-joint disease activity score (DAS28) and clinical disease activity index (CDAI) by treatment group at baseline, weeks 12 and 24. Results: A total of 2970 patients was included with a median (min–max) age of 60.0 (19.0–94.0) years and median (min–max) duration of RA before first bDMARD treatment of 6.0 (0.2–58.3) years. A total of 1177 patients received more than one bDMARD during the analysis period of 1 January 1997 to 15 August 2015. Patients had 4922 treatment ‘episodes’ (defined as a cycle of continuous individual bDMARD prescribing in a single patient). Patients received a mean (SD) of 1.7 (1.0) episodes of treatment with median (min–max) treatment duration of 0.7 (0–11.8) years; median treatment duration was higher with the first treatment episode. bDMARD were most commonly initiated in combination with methotrexate (73.9% of episodes) and least commonly as monotherapy (9.9% of episodes). Median (min–max) baseline DAS28 decreased from 5.3 (0–8.7) with the first bDMARD to 3.7 (0–8.8) with the second. Median baseline CDAI similarly decreased. Conclusions: Patients tended to persist longer on their first bDMARD treatment. bDMARD as monotherapy or in combination appear to be accepted treatment strategies in the real world | en_AU |
| dc.format.mimetype | application/pdf | en_AU |
| dc.identifier.issn | 1444-0903 | en_AU |
| dc.identifier.uri | http://hdl.handle.net/1885/220536 | |
| dc.language.iso | en_AU | en_AU |
| dc.publisher | Blackwell Science Asia | en_AU |
| dc.rights | © 2018 Royal Australasian College of Physicians | en_AU |
| dc.source | Internal Medicine Journal | en_AU |
| dc.source.uri | https://onlinelibrary.wiley.com/doi/full/10.1111/imj.14028 | en_AU |
| dc.subject | rheumatoid arthritis | en_AU |
| dc.subject | persistence | en_AU |
| dc.subject | biologic DMARD | en_AU |
| dc.subject | monotherapy | en_AU |
| dc.subject | OPAL-QUMI | en_AU |
| dc.title | Effectiveness of biologics in Australian patients with rheumatoid arthritis: a large observational study: REAL | en_AU |
| dc.type | Journal article | en_AU |
| local.bibliographicCitation.issue | 10 | en_AU |
| local.bibliographicCitation.lastpage | 1192 | en_AU |
| local.bibliographicCitation.startpage | 1185 | en_AU |
| local.contributor.affiliation | Nicholls, Dave, Coast Joint Care | en_AU |
| local.contributor.affiliation | Barrett, Rina, Roche Products Pty Limited | en_AU |
| local.contributor.affiliation | Button, Peter, Roche Products Pty Limited | en_AU |
| local.contributor.affiliation | Truman, Matt, Roche Products Pty Limited | en_AU |
| local.contributor.affiliation | BIRD, Paul, Combined Rheumatology Practice | en_AU |
| local.contributor.affiliation | Roberts, L, Monash University | en_AU |
| local.contributor.affiliation | Tymms, Kathleen, College of Health and Medicine, ANU | en_AU |
| local.contributor.affiliation | Littlejohn, Geoffrey, Monash University | en_AU |
| local.contributor.affiliation | Griffiths, Hedley, Barwon Rheumatology Service | en_AU |
| local.contributor.authoruid | Tymms, Kathleen, u5095765 | en_AU |
| local.description.embargo | 2099-12-31 | |
| local.description.notes | Imported from ARIES | en_AU |
| local.identifier.absfor | 110322 - Rheumatology and Arthritis | en_AU |
| local.identifier.absseo | 920116 - Skeletal System and Disorders (incl. Arthritis) | en_AU |
| local.identifier.ariespublication | u5234101xPUB288 | en_AU |
| local.identifier.citationvolume | 48 | en_AU |
| local.identifier.doi | 10.1111/imj.14028 | en_AU |
| local.publisher.url | https://onlinelibrary.wiley.com/doi/full/10.1111/imj.14028 | en_AU |
| local.type.status | Published Version | en_AU |
Downloads
Original bundle
1 - 1 of 1
Loading...
- Name:
- 01_Nicholls_Effectiveness_of_biologics_in_2018.pdf
- Size:
- 1.78 MB
- Format:
- Adobe Portable Document Format